本帖最后由 老马 于 2013-3-13 13:43 编辑
Z G/ f+ x3 G: B R, V# ~" R
/ U+ e, }& P) x2 E2 f% a, n健择(吉西他滨)+顺铂+阿瓦斯汀
$ w! \9 Z. \5 \5 n8 \! M% I" S Gemzar +Cisplatin + Avastin* `! Q! K4 b" E# o1 R* x+ V
http://annonc.oxfordjournals.org/content/21/9/1804.full1 \# I: o& L4 z- o! x0 i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
( x5 G- A" a }: w: ]Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 R# ?3 p3 X) r# |0 m0 o1 x3 e
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 9 P' u7 h8 ~. _
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 920)
d7 B4 z+ L( S2 `
华为网盘附件:' M- J* ^" P6 s) D/ [' N8 ]
【华为网盘】ava.JPG+ n6 F1 ^0 n% T. c* {. m/ L. M
|